Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 112809-51-5 | Product Number: L0248
Letrozole
Purity: >98.0%(T)(HPLC)
- 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole
- 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | L0248 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__7H__1__1N__5 = 285.31 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 112809-51-5 |
| Reaxys Registry Number | 6813913 |
| PubChem Substance ID | 172089003 |
| Merck Index (14) | 5450 |
| MDL Number | MFCD00866241 |
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 183.0 to 187.0 °C |
| NMR | confirm to structure |
| Melting Point | 185 °C |
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Methanol |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 + H312 + H332 : Harmful if swallowed, in contact with skin or if inhaled. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
| RTECS# | DI4957000 |
| HS Number | 2933998090 |
References
- Highly selective inhibition of estrogen biosynthesis by CGS 20267 (Letrozole), a new non-steroidal aromatase inhibitor
- Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
- Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status
- Aromatase inhibitors in the treatment of breast cancer (a review)
- Letrozole: a review of its use in postmenopausal women with advanced breast cancer
- High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.